Human GM-CSF / CSF2 (Fc Tag) recombinant protein

Human GM-CSF / CSF2 (Fc Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.

Granulocyte-macrophage colony-stimulating factor

MGI-IGM; CSF2; MGC138897; GM-CSF; MGC131935; GMCSF; CSFGM; MGC151255; MGC151257

P04141

CSF2; GMCSF

Human Cells

A DNA sequence encoding the mature form of human GM-CSF (NP_000749.2) (Ala 18-Glu 144) was fused with the Fc region of human IgG1 at the N-terminus.

Human

The recombinant human GM-CSF/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 364 amino acids and has a predicted molecular mass of 41 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh GM-CSF/Fc monomer is approximately 48-55 kDa due to glycosylation.

> 97 % as determined by SDS-PAGE

1. Measured by its binding ability in a functional ELISA.
Immobilized CD131 at 10 μg/ml (100 μl/well) can bind recombinant human GM-CSF / Fc with a linear range of 0.032-4 μg/ml.
2. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED₅₀ for this effect is typically 1-5 ng/mL.